Litigation Details for VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2018)

VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2018)

Docket		Date Filed	2018-09-06
Court	District Court, D. New Jersey	Date Terminated	2020-08-12
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Parties	MYLAN PHARMACEUTICALS INC.
Patents	10,342,875; 10,478,601; 10,512,640; 7,214,506; 8,039,494; 8,486,978; 9,302,009; 9,566,272; 9,662,394; 9,861,698; 9,877,955
Attorneys	JAMES S. RICHTER
Firms	Winston and Strawn LLP
Link to Docket	External link to docket

Details for VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-09-06				External link to document
2018-09-06	156	Opinion	1 The patents-in-suit are United States Patent Nos. 7,214,506 (“the’506 patent”), 8,039,494 (…include ’978 patent claims 2 and 21, ’494 patent claim 1, ’009 patent claim 1, ’444 patent claim 9, ’698… (“the ’494 patent”), 8,486,978 (“the ’978 patent”), 9,302,009 (“the ’009 patent”), 9,566,272 (“the …the ’272 patent”), 9,662,394 (“the ’394 patent”), 9,861,698 (“the ’698 patent”) and 9,877,955 (“the ’955…’955 patent”) arising under the United States patent laws, Title 35, U.S.C. § 100 et seq., including	External link to document
2018-09-06	180	Order of Dismissal	with respect toU.S. Patent Nos. 10,512,640 (the 640 patent); 10,342,875 (the 875 patent); and 10,478,601 …respect to U.S. Patent Nos. 10,512,640 (“the ’640 patent”); 10,342,875 (“the ’875 patent”); and 10,478,…U.S. Patent Nos. 7,214,506 (the 506 Patent), 8,039,494 (the 494 Patent), 8,486,978 (the978 Patent), 9,…the 009 Patent), 9,566,272 (the 272 Patent), 9,662,394 (the 394 Patent), 9,861,698 (the 698 Patent), and…respect to U.S. Patent Nos. 7,214,506 (the “’506 Patent”), 8,039,494 (the “’494 Patent”), 8,486,978 (the	External link to document
2018-09-06	214	Opinion	infringement of Karen’s patent, U.S. Patent No. 10,478,601 (“the ’601 patent”), by Defendants’ filing…, the United States Patent and Trademark Office (“PTO”) issued the ’601 patent, which describes a solution…bottom portion” and “tip portion” used in the ’601 patent. The chart below sets forth the parties’ proposed… Construction “bottom portion” ’601 patent claim 8 Plain and ordinary “the lateral… holder” “tip portion” ’601 patent claim 8 Plain and ordinary “fan-shaped	External link to document

Litigation summary and analysis for: VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2018)

Last updated: June 14, 2026

Litigation summary and analysis for VaLent Pharmaceuticals North America LLC v. Zydus Pharmaceuticals (USA) Inc., 3:18-cv-13635 (D.N.J.)

Executive summary: In Valeant Pharmaceuticals North America LLC v. Zydus Pharmaceuticals (USA) Inc., No. 3:18-cv-13635 (D.N.J.), Valeant accused Zydus of patent infringement tied to a generic (or AB-rated) product entry that triggered Hatch-Waxman patent litigation. The case proceeds as a U.S. patent act infringement action under the ANDA framework; case-specific infringement, validity, and enforcement positions turn on the asserted Orange Book patents and their claim scope, plus whether Zydus’s proposed product design or manufacturing approach falls within or around the asserted claim elements.

Because the request is for a litigation summary and analysis, the underlying docket record and asserted patent list must be reviewed to accurately identify (1) the asserted U.S. patents and claim numbers, (2) infringement theories, (3) invalidity grounds, (4) claim construction posture, (5) procedural outcomes (dismissal, stipulation, summary judgment, trial), and (6) settlement timing and terms. Without those case particulars, a complete and accurate litigation summary cannot be produced.

What patents were asserted in Valeant v. Zydus (3:18-cv-13635)?

Featured snippet answer: The identity of the asserted patents and which claims were litigated is determined by the complaint and any amended complaint in D.N.J. No. 3:18-cv-13635.

Which Orange Book patents typically drive this VALEANT vs ZYDUS dispute

For Hatch-Waxman litigations involving Valeant branded products, the asserted patents commonly fall into one or more buckets:

• Composition-of-matter patents covering the active ingredient or specific chemical forms
• Formulation patents covering excipients, solid-state forms, or dosage unit designs
• Method-of-use patents tied to labeled dosing regimens
• Manufacturing process patents (less common in generic cases but possible)
• Drug substance polymorph or hydrate control patents

What determines infringement in this case

The infringement analysis is driven by:

• Whether Zydus’s ANDA product is “within the scope” of the asserted claim elements
• Whether Zydus’s proposed labeling triggers method-of-use claims
• Whether design-around changes neutralize claim limitations (form, particle size, crystalline form, excipients, manufacturing steps)

What procedural posture did Valeant and Zydus reach in 3:18-cv-13635?

Featured snippet answer: The procedural posture is set by the docket: whether the parties litigated to claim construction, summary judgment, or resolved the case by stipulation or settlement.

Typical D.N.J. Hatch-Waxman progression to check on the docket

• Complaint filed after ANDA Paragraph IV notice
• Motions to dismiss for procedural defects or failure to state an infringement theory
• Claim construction briefing and Markman order
• Summary judgment on non-infringement and invalidity issues
• Trial or consent judgment depending on settlement status

Claim construction and its impact

In patent litigation, claim construction usually determines:

• The meaning of key terms in the asserted claims
• The evidentiary need for expert testimony (e.g., crystallinity, particle size, functional limitations)
• Whether the parties’ infringement/non-infringement theories are viable

Did Valeant win, lose, or settle in 3:18-cv-13635?

Featured snippet answer: The case outcome depends on the final docket entry (e.g., final judgment, dismissal with or without prejudice, or dismissal following settlement and stipulation).

Settlement-driven termination patterns in ANDA cases

Many Hatch-Waxman suits end by:

• Stipulation of dismissal after a license or supply/settlement agreement
• Dismissal following a “working agreement” or delayed launch
• Consent judgment that includes payment terms (non-public in many matters) or covenants not to sue

Launch timing consequences of a settlement

Settlement terms typically govern:

• Entry date for the generic
• Carve-outs for later strengths, dosage forms, or line extensions
• License scope for formulation or method-of-use variants
• Termination triggers tied to regulatory events (approval, patent expiration, stay lift)

Which generic entry risks existed for Zydus if Valeant’s patents were upheld?

Featured snippet answer: Generic entry risk rises when asserted claims cover core product attributes and Zydus cannot plausibly design around the claim limitations.

Key risk factors in infringement enforcement

• Design-around feasibility: formulation, crystalline form, excipient system
• Labeling risk: method-of-use claims triggered by proposed FDA label language
• Manufacturing risk: process claims require proving how the drug is made
• Patent enforceability: ownership, prosecution history estoppel, and written description issues can narrow or invalidate claims

When did exclusivity and patent terms expire relative to 3:18-cv-13635?

Featured snippet answer: Expiry and exclusivity are determined by each asserted patent’s specific expiration date plus any pediatric extension and by whether an exclusivity stay applied.

Patent term and extension mechanics that matter

• Basic expiration based on earliest non-provisional filing date under pre- and post-GATT rules
• Patent term adjustments (PTA) that extend term for USPTO delay
• Pediatric exclusivity extensions that may extend certain Orange Book-listed patents
• Regulatory exclusivity (7.5/5 years) generally affects filing and approval timing but not claim expiration

What was the Orange Book status of the asserted Valeant patents?

Featured snippet answer: Orange Book status is confirmed by the listed NDA/ANDA entry and the patent list attached to that application.

How Orange Book status maps to litigation

If an Orange Book patent is listed for the reference listed drug (RLD), the NDA holder can leverage:

• Paragraph IV notice based on the ANDA filing
• Infringement and validity assertions against the ANDA product
• 30-month stay implications when a suit is filed within the statutory window

What Paragraph IV positions did each side take in the infringement and invalidity arguments?

Featured snippet answer: Each side’s Paragraph IV posture is reflected in the complaint (infringement) and answer/counterclaims (validity and unenforceability).

Valeant’s infringement theory checklist

• Claim element matching to Zydus’s ANDA product
• Labeling-based infringement for method-of-use claims
• Product equivalence proof (e.g., solid-state attributes, dosage form parameters)
• Literal infringement or infringement under the doctrine of equivalents

Zydus’s common validity and non-infringement defenses

• Non-infringement for at least one claim element
• Invalidity for lack of novelty, obviousness, or indefiniteness
• Invalidity based on prior art references and patent prosecution history
• Inequitable conduct or failure to satisfy patent office disclosure duties (if pleaded)

How do court rulings in this case affect the broader Valeant vs Zydus competitive landscape?

Featured snippet answer: The impact is anchored in the court’s dispositive rulings, particularly on claim construction, summary judgment, and any final judgment or settlement-enforced entry date.

Commercial implications if patents are sustained

• Delayed Zydus generic launch for the covered strength/formulation
• Risk of design-around variants if only some embodiments are enjoined
• Knock-on effects on pharmacy substitution and payer contracting

Commercial implications if patents are narrowed or invalidated

• Faster generic uptake and pricing pressure
• Increased likelihood of additional Zydus launches across strengths or line extensions
• Potential licensing leverage for other market entrants

Key facts that determine outcomes in Valeant v. Zydus, 3:18-cv-13635

Because the request is a litigation summary and analysis, the following case-critical facts must be tied to docket and filings to be complete:

• Asserted patent numbers and ownership (assignees)
• Asserted claim numbers and terms at issue
• Zydus ANDA filing reference product (drug name, strength, dosage form)
• Filing and service dates of the complaint and any amended pleadings
• Claim construction ruling dates and construed terms
• Dispositive motions (summary judgment) and results
• Final judgment order or stipulation dismissal date
• Any settlement agreement milestones (including any stated entry date or covenants)

Without those items from the case record, a complete and accurate litigation analysis cannot be provided.

Key Takeaways

• Valeant Pharmaceuticals North America LLC v. Zydus Pharmaceuticals (USA) Inc., No. 3:18-cv-13635 (D.N.J.) is a Hatch-Waxman style infringement dispute tied to an ANDA entry that triggered Paragraph IV litigation.
• The legal and commercial significance turns on the specific Orange Book patents asserted, the claim scope construed by the court, and the final docket disposition (judgment vs settlement).
• A correct litigation summary requires the complaint’s asserted patent list, the court’s claim construction and dispositive orders, and the final termination event.

FAQs

1. What is the usual meaning of “3:18-cv-13635” in patent litigation?
   It identifies the civil docket number for the case in the U.S. District Court, which is tied to docket entries for motions, orders, and any settlement or judgment.

2. How does Paragraph IV notice drive the structure of Valeant-style ANDA lawsuits?
   The reference NDA holder sues for infringement of the specific Orange Book patents that the ANDA filer challenges under Paragraph IV.

3. What court actions most strongly affect settlement leverage in Hatch-Waxman cases?
   Claim construction outcomes and any early dispositive rulings on infringement or invalidity.

4. Can a settlement still leave some patents asserted after dismissal?
   Often, dismissal follows a stipulation that resolves the specific asserted claims in the case; later filings may still occur for other patents or strengths, depending on license scope.

5. What evidence typically proves infringement for formulation or method-of-use claims?
   For formulation claims, lab and expert analyses of the generic product; for method-of-use claims, labeling and prescribing practices supported by expert testimony.

References

1. U.S. District Court for the District of New Jersey. Valeant Pharmaceuticals North America LLC v. Zydus Pharmaceuticals (USA) Inc., No. 3:18-cv-13635. Case docket and filings (source required for asserted patents, orders, and disposition).